MD-reviewed ·  Healthcare editorial
MedAI Verdict
All comparisons

Head-to-head  ·  Radiology

DeepHealth vs HeartFlow

DeepHealth and HeartFlow both compete in radiology, but answer different questions. DeepHealth is our pick for global radiology AI portfolio: World's largest after Gleamer acquisition (March 2026). HeartFlow earns the reimbursable CCTA AI slot: Non-invasive CCTA-derived FFR, reimbursable since CPT 75577 (Jan 2026). The right choice depends on whether your priority is global radiology ai portfolio or reimbursable ccta ai.

Category
Radiology
Tools compared
02
Reviewed
May 23, 2026
Editorial silo
/best-ai-radiology

The two contenders

Best global radiology AI portfolio

DeepHealth

by RadNet

RadNet's clinical AI suite, world's largest after Gleamer acquisition (March 2026).

Pricing
Enterprise per-site / per-study.
Compliance

Best reimbursable CCTA AI

HeartFlow

by HeartFlow

Non-invasive CCTA -> FFR + plaque analysis (reimbursable).

Pricing
Enterprise (per-study, reimbursable).
Compliance
FDA De Novo / CE-IVDR

Side-by-side specifications

How DeepHealth and HeartFlow compare

Pricing, compliance, and integrations sourced from vendor documentation. Verified May 23, 2026.

SpecDeepHealthHeartFlow
PricingEnterprise per-site / per-study.Enterprise (per-study, reimbursable).
Free tierYesYes
HIPAANo / unverifiedNo / unverified
SOC 2 Type IINo / unverifiedNo / unverified
EHR integrationsNot specifiedNot specified
Founded
HQUSUS
Best forBest global radiology AI portfolioBest reimbursable CCTA AI

Scroll horizontally to see both columns.

Editorial verdict

When to pick each one

When to pick DeepHealth

Best global radiology AI portfolio

World's largest after Gleamer acquisition (March 2026).

  • RadNet-owned
  • CXR, mammography, CT, MRI
  • ~$140M ARR projected EOY 2026
  • Spans CV + onc + neuro
Read the full DeepHealth review

When to pick HeartFlow

Best reimbursable CCTA AI

Non-invasive CCTA-derived FFR, reimbursable since CPT 75577 (Jan 2026).

  • Most clinical-evidence-backed CCTA AI
  • IPO filed 2026
  • Eliminates invasive angiography for many patients
Read the full HeartFlow review

Wider context

Open the full radiology comparison

Acute-care triage, mammography screening, CCTA plaque analysis, mobile MRI. 30+ FDA-cleared platforms across stroke, oncology, cardiac. Enterprise sales only — we compared what's deployed where.

See all radiology

/best-ai-radiology